European Society of Cardiology / European Atherosclerosis Society 2019 Dyslipidemia Treatment Guideline: What Has Changed? Avrupa Kardiyoloji Derneği/Avrupa Ateroskleroz Derneği 2019 Dislipidemi Tedavi Kılavuzu: Değişen Neler Var?
Eurasian Journal of Family Medicine, cilt.9, sa.4, ss.187-198, 2020 (Scopus, TRDizin)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 9 Sayı: 4
- Basım Tarihi: 2020
- Doi Numarası: 10.33880/ejfm.2020090401
- Dergi Adı: Eurasian Journal of Family Medicine
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.187-198
- Anahtar Kelimeler: dyslipidemia, guidelines, LDL cholesterol, risk assessment
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
After 3 years, European Society of Cardiology and the European Atherosclerosis Society published the new guideline for the management of dyslipidemias on August 2019. Comparing with the 2016 version, based on the latest prospective studies, randomized trials and Mendelian randomization studies, there are major changes in the recommendations; especially in the areas of total cardiovascular risk estimation, treatment targets and management of treatment, focusing on the combination therapy. Aforementioned studies indicated that it is possible to prevent atherosclerotic cardiovascular diseases by reducing low density lipoprotein cholesterol as early as and as much as possible since there is a correlation between the concentration of low density lipoprotein cholesterol in the blood and the risk of atherosclerotic cardiovascular diseases. In the light of those information the recommendation for patients at very high risk was changed as a low density lipoprotein cholesterol goal of <55 mg/dL and a low density lipoprotein cholesterol reduction of ≥50% from the baseline value which was previously defined as <70 mg/dL. For patients with high, moderate and low risks, the low density lipoprotein cholesterol goals are defined as <70 mg/dL, <100 mg/dL and <116 mg/dL, respectively. Since no adverse effect of reducing the low density lipoprotein cholesterol too much was demonstrated so far, the guidelines support “lower is better” message for low density lipoprotein cholesterol levels.